Core Points - AEON Biopharma, Inc. announced a 1-for-72 reverse stock split to comply with NYSE American requirements [1][2] - The reverse stock split will take effect on February 26, 2025, with trading resuming under the existing ticker symbol "AEON" [2] - The ownership percentage of each stockholder will remain unchanged, except for fractional shares, which will be rounded up [3] Company Overview - AEON is a clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for medical conditions, particularly in the neurosciences market [5] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use by Evolus under the name Jeuveau and is approved as a biosimilar in Mexico and India [5] - The company has exclusive rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, UK, and other territories, and has a management team experienced in biopharmaceutical development [5]
AEON Biopharma, Inc. Announces Reverse Stock Split